Us Apixaban Market Size By Applications, By Type, By End-User, By Deployment & By Technology 2032
Apixaban Market was valued at USD 2.5 Billion in 2022 and is projected to reach USD 5.8 Billion by 2030, growing at a CAGR of 11.4% from 2024 to 2030.
Apixaban, marketed under the brand name Eliquis, is a direct oral anticoagulant (DOAC) that has revolutionized the management of thromboembolic disorders in the United States. Its primary applications include preventing stroke in patients with non-valvular atrial fibrillation and treating deep vein thrombosis (DVT) and pulmonary embolism (PE). The U.S. market for apixaban has experienced significant growth, driven by its efficacy, safety profile, and the increasing prevalence of conditions like atrial fibrillation and venous thromboembolism.
As of 2024, the apixaban market in the U.S. was valued at approximately $2.92 billion, with projections indicating a compound annual growth rate (CAGR) of 8.7% through 2025. This growth is attributed to several factors:
Rising Incidence of Atrial Fibrillation: The aging population has led to a higher number of individuals diagnosed with atrial fibrillation, thereby increasing the demand for effective anticoagulant therapies like apixaban.
Shift from Warfarin to NOACs: Patients and healthcare providers are increasingly favoring newer oral anticoagulants (NOACs) over traditional therapies like warfarin due to their ease of use and more favorable safety profiles.
Regulatory Approvals and Expansions: The approval of generic versions of apixaban has made the medication more accessible, contributing to market growth.
In terms of market segmentation, apixaban is predominantly administered in tablet form, with hospitals and clinics being the primary distribution channels. The drug's widespread adoption is also influenced by its favorable clinical outcomes and the convenience of oral administration, which eliminates the need for regular monitoring associated with some other anticoagulants.
Looking ahead, the U.S. apixaban market is expected to continue its upward trajectory, with forecasts estimating a market size of $4.48 billion by 2029. This growth is anticipated to be driven by ongoing clinical research, expanding indications, and the increasing burden of thromboembolic diseases. However, challenges such as the high cost of branded apixaban and the potential for generic competition remain considerations for stakeholders in the healthcare industry.
Get an In-Depth Research Analysis of the Global Apixaban Market Size And Forecast [2025-2032]
Pfizer
Medichem
Polpharma
Beijing Cooperate Pharmaceutical
Centaur Pharmaceutical
DEAFARMA
Dipharma Francis
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the Global Apixaban Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the Global Apixaban Market
Factor Xa Inhibitors
Anticoagulants
Direct Oral Anticoagulants (DOACs)
Stroke Prevention in Atrial Fibrillation
Treatment of Deep Vein Thrombosis (DVT)
Pulmonary Embolism (PE) Treatment
Prophylaxis for DVT Following Surgery
Hospitals
Outpatient Clinics
Pharmacies
Home Healthcare Settings
Adults (18-64 years)
Seniors (65+ years)
Direct Sales
Pharmaceutical Wholesalers
Online Pharmacies
Retail Pharmacies
Global (United States, Global and Mexico)
Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
South America (Brazil, Argentina, Columbia, etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
For More Information or Query, Visit @ Apixaban Market Research Analysis
1. Introduction of the Global Apixaban Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. Global Apixaban Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. Global Apixaban Market, By Type
6. Global Apixaban Market, By Application
7. Global Apixaban Market, By Geography
Global
Europe
Asia Pacific
Rest of the World
8. Global Apixaban Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading Global Research and Consulting firm servicing over 5000+ global clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/